METVIX 168 MG
METHYL AMINOLEVULINATE (METHYL AMINOLEVULINATE HYDROCHLORIDE) : 168 MG · DIN 02323273 · GALDERMA CANADA INC
Health Canada status: MARKETED
What is METVIX?
METVIX 168 MG contains METHYL AMINOLEVULINATE (METHYL AMINOLEVULINATE HYDROCHLORIDE) : 168 MG. It is listed in the Health Canada Drug Product Database under DIN 02323273, held by GALDERMA CANADA INC, supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 16-Jun-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is METVIX used for?
Treatment of thin or non-hyperkeratotic and non-pigmented actinic keratosis (face/scalp) and primary superficial basal cell carcinoma (outside H-zone of face).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02323273 |
|---|---|
| Brand name | METVIX |
| Generic / active ingredient | METHYL AMINOLEVULINATE (METHYL AMINOLEVULINATE HYDROCHLORIDE) : 168 MG |
| Manufacturer | GALDERMA CANADA INC |
| Strength | 168 MG |
| Dosage form | CREAM |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | L01XD03 METHYL AMINOLEVULINATE |
| AHFS class | 84:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Jun-2009 |
| Original market date | 2009-06-16 00:00:00 |
How is it administered?
AK: One session (c-PDT or DL-PDT), evaluate at 3 months. sBCC: One session (c-PDT), second session 7 days later. Max 2g cream per session. Administered by healthcare professionals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents points to section 11, but text ends at section 8.2).
How is it supplied?
2 gram aluminum tube sealed with an aluminum membrane and a screw cap.
Contraindications
Hypersensitivity to methyl aminolevulinate, aminolevulinic acid, peanut/almond oil; cutaneous photosensitivity/porphyria; morpheaform basal cell carcinoma.
Warnings and precautions
Administer by trained professionals only. Avoid eyes/mucous membranes. Pain during illumination may induce high blood pressure. Risk of transient global amnesia. Potential for skin sensitization.
Who else supplies METHYL AMINOLEVULINATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYL AMINOLEVULINATE appears in 14 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.